Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II vicagrel dose-comparison trial in coronary atherosclerotic heart disease patients undergoing PCI
ChiCTR1800017069Phase 2Not yet recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of vicagrel in coronary arteriosclerosis (4 arms), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Inhibition of platelet aggregation. Planned start Jul 2018; status: not yet recruiting.
02
Drugs
vicagrel
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1800017069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017069.